54540-58-8

Usage

Uses

Used in Chemical Synthesis:
1-(4-chlorobutyl)-4-fluorobenzene is used as an intermediate compound for the synthesis of other chemical substances. Its reactive chloroand fluorogroups make it a valuable component in various chemical reactions, contributing to the production of a wide range of chemical products.
Used in Pharmaceutical Industry:
1-(4-chlorobutyl)-4-fluorobenzene is used as a building block in the development of new pharmaceutical compounds. Its unique structure and reactivity allow for the creation of novel drug molecules with potential therapeutic applications.
Used in Material Science:
1-(4-chlorobutyl)-4-fluorobenzene is used as a component in the synthesis of advanced materials, such as polymers and composites, with specific properties tailored for various applications in material science.

InChI:InChI=1/C10H12ClF/c11-8-2-1-3-9-4-6-10(12)7-5-9/h4-7H,1-3,8H2

Upstream product

• 3874-54-2 4-(4-fluorophenyl)-4-oxo-n-butyl chloride 
• 6940-78-9 4-chlorobutyl bromide 
• 352-13-6 4-flourophenylmagnesium bromide 
• 84648-52-2 C₁₈H₁₆ClFO₄ 
• 84648-70-4 C₁₃H₁₅FO₄ 

Downstream Products

• 99579-51-8 1'-[4-(4-fluorophenyl)butyl]-7-chloro-2-methylspiro[2H-1,4-benzodioxepin-3(5H)4'-piperidine]hydrochloride 
• 99579-50-7 1'-[4-(4-fluorophenyl)butyl]-7-fluoro-2-methylspiro[2H-1,4-benzodioxepin-3(5H)4'-piperidine]hydrochloride 
• 1366348-85-7 3-(4-chlorophenyl)-8-(4-(4-fluorophenyl)butyl)-8-azabicyclo[3.2.1]octan-3-ol hydrochloride 
• 1610700-27-0 1-(4-(4-fluorophenyl)butyl)-4-(5-methylpyridin-2-yl)piperazine 
• 164668-08-0 4-(4'-chlorophenyl)-1-(4'-(4-fluorophenyl)butyl)piperidin-4-ol 
• 88144-45-0 1'-[4-(4-Fluorophenyl)butyl]-2-methylspiro[2H-1,4-benzodioxepin-3(5H)4'-piperidine]hydrochloride 
• 55395-96-5 4-[4-(4-fluoro-phenyl)-butyl]-6-phenyl-3,4,5,6-tetrahydro-2H-2,6-methano-benzo[g][1,4]oxazocin-8-ol 

Relevant academic research and scientific papers

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol

Structure-activity relationship studies on 4-(4-(4-chlorophenyl)-1,4- diazepan-1-yl)-1-(4-fluorophenyl)butan-1-one (SYA 013), a homopiperazine analog of haloperidol has resulted in an understanding of the effect of structural modifications on binding affinity at dopamine and serotonin receptor subtypes. Further exploration, using bioisosteric replacement strategies has led to the identification of several new agents including compounds 7, 8, 11 and 12 which satisfy the initial criteria for further exploration as new antipsychotic agents. In addition, compound 18, a D3 selective tropanol, has been identified as having the potential for further optimization into a useful drug which may combat neuropsychiatric diseases.

Functional group tolerant Kumada-Corriu-Tamao coupling of nonactivated alkyl halides with aryl and heteroaryl nucleophiles: Catalysis by a nickel pincer complex permits the coupling of functionalized Grignard reagents

A nickel(II) pincer complex [(MeNN2)NiCl] (1) catalyzes Kumada-Corriu-Tamao cross coupling of nonactivated alkyl halides with aryl and heteroaryl Grignard reagents. The coupling of octyl bromide with phenylmagnesium chloride was used as a test reaction. Using 3 mol % of 1 as the precatalyst and THF as the solvent, and in the presence of a catalytic amount of TMEDA, the coupling product was obtained in a high yield. The reaction conditions could be applied to cross coupling of other primary and secondary alkyl bromides and iodides. The coupling is tolerant to a wide range of functional groups. Therefore, alkyl halides containing ester, amide, ether, thioether, alcohol, pyrrole, indole, furan, nitrile, conjugated enone, and aryl halide moieties were coupled to give high isolated yields of products in which these units stay intact. For the coupling of ester-containing substrates, O-TMEDA is a better additive than TMEDA. The reaction protocol proves to be efficient for the coupling of Knochel-type functionalized Grignard reagents. Thus aryl Grignard reagents containing electron-deficient and/or sensitive ester, nitrile, amide, and CF3 substituents could be successfully coupled to nonactivated and functionalized alkyl iodides. The catalysis is also efficient for the coupling of alkyl iodides with functionalized heteroaryl Grignard reagents, giving rise to pyridine-, thiophene-, pyrazole-, furan-containing molecules with additional functionalities. Concerning the mechanism of the catalysis, [(MeNN2)Ni-(hetero)Ar] was identified as an intermediate, and the activation of alkyl halides was found to take place through a radical-rebound process.

Indole derivatives as 5-HT1A and/or 5-HT2 ligands

Pharmacologically active indole derivatives having central serotonergic activity and useful in the treatment of CNS disorders of formula (I) wherein R, R1 and R2 have the meanings in the specification. STR1

Structure of ω-Arylalkyl Radicals: A 13C CIDNP Investigation

Thermolysis of a series of ω-arylalkanoyl m-chlorobenzoyl (and acetyl) peroxides at ca. 100 deg C in cyclohexanone and in hexachloroacetone was studied by using 13C chemically induced dynamic nuclear polarization.Analysis of the observed 13C polarizations indicate that all the three radicals (β-arylethyl, γ-arylpropyl and δ-arylbutyl) have open-chain structures with no evidence for aryl participation resulting in spirocycloalkylcyclohexadienyl radicals.

Drugs derived from cannabinoids. 5. Δ(6a,10a) Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains

Ten new Δ(6a,10a) THC analogs with arylalkyl side chains, one with a dimethylaminoalkyl side chain, and six heterocyclic Δ(6a,10a) THC analogs [8 substituted 5,5 dimethyl 10 hydroxy 2 (2 propynyl) 1,2,3,4 tetrahydro 5H [1] benzo pyranol [4,3 c] pyridines] were prepared. They showed pharmacological activity as analgesics, tranquilizers, antihypertensives, and hypnotics and as antisecretory, antiulcer, and antidiarrheal agents. The most potent compounds had either a 1 methyl 4 (4 fluorophenyl) butyl or a 1,2 dimethyl 4 (4 fluorophenyl) butyl side chain.